Chelating agent used in chronic thalassemia major for iron overload
**Core Concept**
Chronic thalassemia major is characterized by excessive iron absorption due to frequent blood transfusions, leading to iron overload. A chelating agent is used to remove excess iron from the body, thereby reducing the risk of complications such as cardiac dysfunction and diabetes.
**Why the Correct Answer is Right**
Deferoxamine is a chelating agent that binds to iron ions, forming a stable complex that is excreted by the kidneys. It is administered subcutaneously, usually at night, to maximize its effectiveness. Deferoxamine is particularly useful in managing iron overload in patients with chronic thalassemia major, as it can effectively reduce serum iron levels and prevent tissue damage.
**Why Each Wrong Option is Incorrect**
**Option A:** Succimer is a chelating agent used to treat lead poisoning, but it is not effective in removing iron from the body. It is primarily used to mobilize lead from the body and is not indicated for iron overload.
**Option B:** Penicillamine is a chelating agent used to treat heavy metal poisoning, including copper and mercury, but it is not effective in managing iron overload. It is also associated with a higher risk of adverse effects compared to deferoxamine.
**Option C:** Desferoxamine is the correct answer, but this option is missing. However, it seems to be a typo, and the correct answer is indeed Deferoxamine.
**Clinical Pearl / High-Yield Fact**
Deferoxamine is a critical component of iron chelation therapy in chronic thalassemia major, and its use should be carefully monitored to avoid iron deficiency and other adverse effects.
**Correct Answer: . Deferoxamine**